DDInter1804 DDInter899
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Ticlopidine {u} (Compound) binds {v} (Gene) MPO
Ticlopidine {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Ticlopidine {u} (Compound) downregulates {v} (Gene) RPS4Y1
Ticlopidine {u} (Compound) causes {v} (Side Effect) Flatulence
Ticlopidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Ticlopidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alteplase
Ticlopidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Drotrecogin alfa
Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Ticlopidine (Compound) binds MPO (Gene)
Ticlopidine (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Ticlopidine (Compound) downregulates RPS4Y1 (Gene)
Ticlopidine (Compound) causes Flatulence (Side Effect)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Alteplase
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ticlopidine may lead to a major life threatening interaction when taken with Drotrecogin alfa